四川医学2018，Vol.39Issue(2)：119-122,4.DOI:10.16252/j.cnki.issn1004-0501-2017.
贝伐单抗在晚期结直肠癌患者治疗中安全性临床研究
Clinical Study on the Safety of Bevacizumab in the Treatment of Patients with Advanced Colorectal Cancer
摘要
Abstract
Objective To study the safety of bevacizumab in the treatment of colorectal cancer,in order to provide some guidance for the clinical application.Methods A retrospective analysis of 72 patients with advanced colorectal cancer who were admitted to our hospital and treated with bevacizumab was conducteol.Adverse reactions and incidence of bevacizumab were col-lected.A single variable and multivariate analysis was used to determine the potential risk factors for the adverse reactions of bev-acizumab.Results A total of 72 patients were evaluable for safety.The most common adverse drug reactions were hypertension (12.5%),hemorrhage(12.5%),and proteinuria(8.3%).The incidence of serious adverse drug reactions was low: the inci-dence of bleeding was 1.4 %,the incidence of venous thromboembolism was 1.4 %,and the incidence of gastrointestinal perfora-tion was 1.4 %.The high risk factors of adverse drug reactions were identified by multivariate analysis.Conclusion Bevacizumab has a low incidence of serious adverse events.Patients with advanced or metastatic colorectal cancer have better safety and better tolerance to bevacizumab.关键词
晚期结直肠癌/贝伐单抗/安全性Key words
advanced colorectal cancer/bevacizumab/safety分类
医药卫生引用本文复制引用
赵磊,王婧,车娟娟,李卉惠,曹邦伟..贝伐单抗在晚期结直肠癌患者治疗中安全性临床研究[J].四川医学,2018,39(2):119-122,4.基金项目
北京市医院管理局"青苗"计划专项经费资助(编号:QML20170102) （编号:QML20170102）
北京友谊医院院启动基金(编号:yyqdkt 2015-10) （编号:yyqdkt 2015-10）
北京市自然科学基金资助(编号:7184200) （编号:7184200）
